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Vascular biology and remodelling 105
key event in vascular proliferative diseases by releasing cytokines and growth
factors. This activation is mediated by Shh and PDGF-BB induced activation of
Smo-dependent signalling and the selective inhibitor GDC-0449 may serve as a
novel and promising therapeutic strategy to prevent neointima formation.
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The novel mineralocorticoid receptor antagonist Finerenone
attenuates neointima formation after vascular injury
R.-J. Musmann1, J. Dutzmann1, J.-M. Daniel1, P. Kolkhof2, J. Bauersachs1,
D.G. Sedding1. 1Hannover Medical School, Hannover, Germany; 2Bayer
HealthCare Pharmaceuticals, Global Drug Discovery, Cardiology Research,
Wuppertal, Germany
Background: Ischemic cardiomyopathy as a result of coronary artery disease
is the leading cause for heart failure. In consequence, the effect of novel heart
failure therapeutics on vascular function and remodeling processes is of pivotal
importance. Finerenone, a novel nonsteroidal mineralocorticoid receptor (MR) an-
tagonist, holds the promise to be safe and efﬁcient in the treatment of patients
with heart failure and/or chronic kidney disease. However, the effects on vascular
function remain elusive.
Purpose: The aim of this study was to determine the functional effect of selective
MR antagonism by Finerenone in vascular cells in vitro and the effect on vascular
remodeling following acute vascular injury in vivo.
Methods and results: Finerenone dose-dependently and signiﬁcantly reduced
aldosterone-induced human coronary artery smooth muscle cell (HCASMC) pro-
liferation as quantiﬁed by BrdU incorporation. Furthermore, Finerenone dose-
dependently and signiﬁcantly prevented aldosterone-induced apoptosis in hu-
man umbilical vein endothelial cells (HUVEC) as measured with a ﬂow cytometry
based FLICA-assay.
In vivo, oral application of Finerenone dose-dependently and signiﬁcantly inhib-
ited intimal and medial cell proliferation following femoral artery wire-induced in-
jury in C57BL/6J mice as quantiﬁed by staining for Ki-67 10 days following injury
(vehicle vs. 1 mg/kg/d vs. 10mg/kg/d; each p<0.01). Concomitantly, Finerenone
attenuated neointimal lesion formation following femoral artery wire-induced in-
jury 21 days following injury (luminal stenosis, vehicle vs. Finerenone 1 mg/kg/d
vs. Finerenone 10mg/kg/d: 90.2±1.1% vs. 60.1±17.3%; p=0.1063 to vehicle,
vs. 35.3±10.0%; p=0.0061 to vehicle; n=8). Furthermore, there was a trend to-
wards an accelerated re-endothelialization of the injured vessel segments in
Finerenone-treated mice three days following electric injury of the murine carotid
artery.
Conclusion: Finerenone treatment signiﬁcantly attenuates HCASMC prolifera-
tion while simultaneously preventing apoptosis of endothelial cells in vitro. This
is reﬂected by a signiﬁcantly reduced neointima formation and reduction of lu-
minal stenosis as well as a trend towards an accelerated endothelial healing of
the injured vessels. Thus, apart from its beneﬁcial effects in heart failure therapy,
Finerenone might provide favorable vascular effects through restoring vascular
integrity and preventing adverse vascular remodeling.
Acknowledgement/Funding: This study is supported by Bayer HealthCare
Pharmaceuticals, Wuppertal, Germany
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Endothelial protein tyrosine phosphatase-1B deletion enhances
neointima formation in mice with diet-induced obesity
A. Hubert1, M. Jaeger1, R. Gogiraju2, T. Muenzel1, K. Schaefer1. 1University
Medical Center of Mainz, Center for Cardiology, Cardiology I, Mainz, Germany;
2Department of Cardiology and Pulmonary Medicine, Goettingen, Germany
Background: Obesity and metabolic dysfunction are associated with increased
expression of protein tyrosine phosphate (PTP)-1B, a negative regulator of re-
ceptor tyrosine kinase signalling, and PTP1B overexpression may be causally
involved in the development of insulin and leptin resistance in obesity. Previous
studies have shown that systemic inhibition or genetic deletion of PTP1B protects
against endothelial dysfunction in heart failure. However, the role of PTP1B ex-
pressed in endothelial cells for the cardiovascular risk in obesity has not been
directly examined so far.
Purpose: To determine the effect of endothelial PTP1B deletion on the vascular
response to injury in mice with diet-induced obesity.
Methods:Mice with loxP-ﬂanked PTP1B alleles were mated with mice expressing
a Cre recombinase-estrogen receptor fusion protein ER (T2) under control of the
endothelial receptor tyrosine kinase (Tie2) promoter. Cre recombinase activity
and endothelial-restricted PTP1B gene excision (End.PTP1B-KO) was induced by
feeding mice tamoxifen-containing rodent chow for 6 weeks. Obesity was induced
by feeding mice 45% high fat diet (HFD) for 4 weeks prior to vascular injury at the
common carotid artery using 10% ferric chloride and continued until sacriﬁce 3
weeks later.
Results: HFD resulted in increased body weight, visceral obesity and total serum
cholesterol, both in End.PTP1B-WT and End.PTP1B-KO mice and also was as-
sociated with elevated PTP1B protein levels in endothelial cells isolated from the
lungs of obese mice (1.4-fold increase vs. lean; P<0.05). Morphometric analy-
sis of serial sections through restenotic lesions revealed that deletion of PTP1B
in endothelial cells was associated with a signiﬁcant increase in the neointima
area (P<0.05) and intima-to-media ratio (P<0.05). Because the total vessel area
also was signiﬁcantly enlarged in mice lacking endothelial PTP1B (P<0.05),
the more pronounced lumen stenosis observed in End.PTP1B-KO mice (33±7.0
vs. 20±4.0% in End.PTP1B-WT) did not reach statistical signiﬁcance. Analysis
of re-endothelisation revealed signiﬁcantly reduced numbers of luminal cell nu-
clei in End.PTP1B-KO animals (P<0.05), and (immuno-)histochemical analysis
conﬁrmed reduced luminal binding of endothelial lectin (10±4.4 vs. 25±5.1% in
End.PTP1B-WT mice; P=0.065). Moreover, neointimal lesions of End.PTP1B-KO
mice were characterised by an increased absolute number of cell nuclei (P<0.05
vs. End.PTP1B-WT mice) as well as elevated amounts of αSM-actin-positive
SMCs (6315±2671 vs. 1729±496 μm2; P=0.075).
Conclusion: Our ﬁndings suggest that endothelial PTP1B plays an important
role for lesion re-endothelisation after vascular injury. The observed neointimal
hyperplasia in mice lacking PTP1B in endothelial cells may be the consequence
of failure to induce SMC quiescence resulting in uncontrolled neointimal SMC
proliferation.
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Endothelial-Mesenchymal Transition: miR-101 as a new target to treat
intimal hyperplasia
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Introduction: Endothelial-Mesenchymal Transition (EndMT) is a speciﬁc form of
endothelial dysfunction wherein endothelial cells acquire a mesenchymal pheno-
type and lose their endothelial functions. We, and others, recently described that
EndMT contributes to intimal hyperplasia and atherosclerosis.
Pro-ﬁbrotic and inﬂammatory cytokines, such as IL-1β and TGFβ2 induce EndMT.
We found that the mitogen activated protein kinase 7 (MAPK7, also known as
Erk5) inhibits EndMT. MAPK7 activation decreases the expression of the histone
methyltransferase Enhancer-of-Zeste homologue 2 (Ezh2) thereby maintaining
endothelial quiescence.This decrease in Ezh2 expression may therefore be re-
sponsible for the protective effects of MAPK7 activation and may thus offer new
therapeutic options for the treatment of endothelial dysfunction and intimal hyper-
plasia.
Ezh2 is the catalytic subunit of the Polycomb Repressive Complex 2 that methy-
lates lysine 27 on histone 3 (H3K27me3). H3K27me3 is a repressive chromatin
mark that inhibits gene expression. Currently, it is elusive how the crosstalk be-
tween MAPK7 and Ezh2 is regulated in the endothelium and if the balance be-
tween MAPK7 and EZH2 is disturbed during intimal hyperplasia.
Methods and results: We used in silico analysis to identify miRNAs that could
evoke posttranscriptional silencing of Ezh2. In Luciferase reporter assays, miR-
101 efﬁciently inhibited expression of the luciferase reporter by interacting with
the 3’UTR of EZH2. Using a uniform laminar ﬂow setup, we revealed that MAPK7
induced miR101 expression, which was blocked by the selective MAPK7 inhibitor
BIX02189 (p<0.05). Furthermore, ectopic expression of miR-101 in endothelial
cells reduced the expression of Ezh2.
In samples of human coronary artery stenosis Ezh2 levels are increased,
whereas MAPK7 expression is reduced. Moreover, miR-101 expression is de-
creased, which associated with the increase of Ezh2 (R2=0.23, p=0.051) and
severity of the stenosis (Intima/Media Thickness, R2=0.45, p=0.003).
Conclusion(s): Under uniform laminar ﬂow MAPK7 inhibits Ezh2 expression via
activation of miR-101. In coronary artery stenosis, endothelial cells are exposed
by non-uniform shear stress which decreases MAPK7 activation, miR-101 ex-
pression and concurrently increases Ezh2 expression, which may cause EndMT
and intimal hyperplasia. Therefore, the restoration of miR-101 expression or the
silencing of Ezh2 in the endothelium might provide novel therapeutic approaches
to treat intimal hyperplasia.
Acknowledgement/Funding: Mongolian Government Scholarship (BV)
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TNF-antagonists improve arterial stiffness in patients with rheumatoid
arthritis: a meta-analysis
A. Gravos, C. Vlachopoulos, G. Georgiopoulos, P. Pietri, D. Terentes-Printzios,
C. Georgakopoulos, K. Stamatelopoulos, D. Tousoulis. Hippokration General
Hospital, Athens, Greece
Background: Patients with rheumatoid arthritis (RA) have a higher arterial stiff-
ness than their age-matched healthy counterparts and an increased inﬂammatory
burden that might be associated with their increased cardiovascular risk. While
tumor necrosis factor alpha (TNF)-antagonists have been found to reduce inﬂam-
matory markers in RA, it is debatable if they have favorable effects on surrogate
markers of cardiovascular outcomes.
Purpose:We conducted a meta- analysis to assess the effect of TNF-antagonists
on arterial stiffness, a predictor of cardiovascular events and mortality, in RA pa-
tients.
Methods: A search of PUBMED was conducted to identify studies into the ef-
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